Clinical Pharmacist-Led Bundled Care Model on Preventable Polypharmacy and Cost Avoidance

Официальное название

Impact of a Clinical Pharmacist-Led Bundled Care Model on Preventable Polypharmacy and Cost Avoidance Among Hospitalized Adults in Oman: A Prospective Randomized Controlled Study

Обзор

This study aims to evaluate whether a clinical pharmacist-led bundled care model can improve medication use and health outcomes in hospitalized adult patients with preventable polypharmacy. Preventable polypharmacy refers to the use of multiple medications when some may no longer be necessary, may be inappropriate, or may increase the risk of medication-related harm. Participants will be randomly assigned to receive either the pharmacist-led bundled care intervention in addition to usual hospital care or usual hospital care alone. The intervention includes comprehensive medication reconciliation, assessment of medication appropriateness, identification of potentially inappropriate medications, individualized deprescribing recommendations when appropriate, patient and caregiver education, discharge medication reconciliation, and follow-up after hospital discharge. The study will compare important clinical outcomes between the two groups, including hospital readmissions, emergency department visits, adverse drug events, medication appropriateness, quality of prescribing, and healthcare costs. The findings will help determine whether integrating a clinical pharmacist-led bundled care model into routine hospital practice can improve patient safety, optimize medication use, and reduce unnecessary healthcare utilization.

Вмешательства

• Другое Clinical Pharmacist-Led Bundled Care
  Participants randomized to the intervention arm will receive a structured clinical pharmacist-led bundled care model in addition to usual hospital care. The intervention includes medication reconciliation at admission, comprehensive medication review, identification and resolution of medication-related problems, assessment of medication appropriateness using validated tools, deprescribing of potentially inappropriate medications when clinically indicated, dose optimization, evaluation of drug-dr
• Другое Control Arm (Usual Care)
  Participants randomized to the control arm will receive usual hospital care provided according to the standard practices of the participating institutions. This includes routine medical and nursing care, medication prescribing and review by the treating healthcare team, and standard discharge processes. No structured clinical pharmacist-led bundled care intervention, standardized comprehensive medication review, protocol-driven deprescribing, or post-discharge pharmacist follow-up will be provid

Первичные конечные точки

• Total Healthcare Cost Avoidance per Participant [Срок оценки: 90 days after hospital discharge]
• Prevalence of Preventable Polypharmacy at Hospital Discharge [Срок оценки: through study completion, an average of 1 week during admission]

Вторичные конечные точки (3)

• Number of Medications Deprescribed per Participant [Срок оценки: through study completion, an average of 1 week during admission]
• Incidence of Adverse Drug Events [Срок оценки: From hospital admission through 90 days after discharge]
• All-Cause Hospital Readmission [Срок оценки: 30 days and 90 days after hospital discharge]

Критерии участия

Критерии включения

• Adults aged 18 years or older.
• Admitted under an adult medical specialty at one of the participating hospitals.
• Receiving five or more regular medications at the time of hospital admission.
• Expected hospital stay of at least 48 hours.
• Able and willing to provide written informed consent.

Критерии исключения

• Admission under obstetric, pediatric, or psychiatric services.
• Admission to an intensive care unit.
• Terminal illness with an expected survival of less than three months.
• Unable to provide informed consent and without an available legal representative.
• Declines participation in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Организация здравоохранения

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07719907 · 188/2026

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗